当前位置:首页 - 行情中心 - 誉衡药业(002437) - 财务分析 - 现金流量表

誉衡药业

(002437)

  

流通市值:76.75亿  总市值:81.39亿
流通股本:21.03亿   总股本:22.30亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,100,814,980.84564,644,445.272,371,185,934.251,847,160,364.27
  收到的税费返还368,869.06247,117.07546,693.48546,693.48
  收到其他与经营活动有关的现金43,987,064.5719,877,053.78108,219,340.2888,834,654.04
  经营活动现金流入小计1,145,170,914.47584,768,616.122,479,951,968.011,936,541,711.79
  购买商品、接受劳务支付的现金197,622,409.55102,849,275.27423,728,767.03278,548,454.92
  支付给职工以及为职工支付的现金144,041,042.5877,458,703.98317,706,963.64250,117,152.68
  支付的各项税费110,138,764.5950,895,460.69241,013,926.27170,860,855.27
  支付其他与经营活动有关的现金511,208,040.12280,854,886.91,224,146,797.6928,750,388.51
  经营活动现金流出小计963,010,256.84512,058,326.842,206,596,454.541,628,276,851.38
  经营活动产生的现金流量净额182,160,657.6372,710,289.28273,355,513.47308,264,860.41
二、投资活动产生的现金流量:
  收回投资收到的现金625,167,380425,167,3801,268,858,383.65933,499,000
  取得投资收益收到的现金6,237,460.993,266,043.6741,481,560.1434,110,196.66
  处置固定资产、无形资产和其他长期资产收回的现金净额19,306,70019,198,00011,420,946.4411,405,365.91
  投资活动现金流入小计650,711,540.99447,631,423.671,321,760,890.23979,014,562.57
  购建固定资产、无形资产和其他长期资产支付的现金7,228,556.724,282,920.3123,814,355.9817,581,670.98
  投资支付的现金717,738,472.22175,000,0001,630,000,0001,290,000,000
  取得子公司及其他营业单位支付的现金--299,343257,556
  投资活动现金流出小计724,967,028.94179,282,920.311,654,113,698.981,307,839,226.98
  投资活动产生的现金流量净额-74,255,487.95268,348,503.36-332,352,808.75-328,824,664.41
三、筹资活动产生的现金流量:
  取得借款收到的现金67,319,650-90,000,00070,000,000
  筹资活动现金流入平衡项目0-00
  筹资活动现金流入小计67,319,650-90,000,00070,000,000
  偿还债务支付的现金70,000,00070,000,000--
  分配股利、利润或偿付利息支付的现金709,145.1340,333.346,830,966.096,387,591.09
  其中:子公司支付给少数股东的股利、利润--5,621,674.435,621,674.43
  支付其他与筹资活动有关的现金3,352,742.453,203,009.72107,219,468.2983,872,599.06
  筹资活动现金流出小计74,061,887.5573,543,343.06114,050,434.3890,260,190.15
  筹资活动产生的现金流量净额-6,742,237.55-73,543,343.06-24,050,434.38-20,260,190.15
四、汇率变动对现金及现金等价物的影响-2,859,825.3-1,436,780.01-1,887,808.59-968,043.41
五、现金及现金等价物净增加额98,303,106.83266,078,669.57-84,935,538.25-41,788,037.56
  加:期初现金及现金等价物余额395,837,152.2395,828,907.76480,772,690.45480,772,690.45
  期末现金及现金等价物余额494,140,259.03661,907,577.33395,837,152.2438,984,652.89
补充资料:
  净利润162,333,510.27-382,357,127.75-
  资产减值准备480,391.82-10,253,095.65-
  固定资产和投资性房地产折旧26,276,552.66-55,603,103.24-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧26,276,552.66-55,603,103.24-
  无形资产摊销17,001,301.64-33,832,277.04-
  处置固定资产、无形资产和其他长期资产的损失-12,520,228.38--3,542,703.45-
  固定资产报废损失73,675.14-610,504.12-
  公允价值变动损失-4,255,315.28--5,977,821.1-
  财务费用1,127,617.71-4,225,254.36-
  投资损失-855,955.72--136,525,191.03-
  递延所得税440,337.95--160,360.82-
  其中:递延所得税资产减少702,399.91--70,640.68-
    递延所得税负债增加-262,061.96--89,720.14-
  存货的减少14,040,907.73--19,218,202.55-
  经营性应收项目的减少-6,564,249.62--6,626,051.17-
  经营性应付项目的增加-17,949,491.75--50,331,385.5-
  其他1,852,751.1-7,498,162.21-
  现金的期末余额494,140,259.03-395,837,152.2-
  减:现金的期初余额395,837,152.2-480,772,690.45-
  现金及现金等价物的净增加额98,303,106.83--84,935,538.25-
公告日期2026-08-272026-04-282026-04-282025-10-29
审计意见(境内)标准无保留意见
TOP↑